Student Pharmacist Perceptions of a Behind-The-Counter Class of Medications

Abstract

Objectives:

To report perceptions of PharmD candidates regarding a behind-the-counter (BTC) class of medications and to identify perceived barriers to its successful implementation.

Methods:

PharmD candidates in their second, third, and fourth professional years were invited to complete an online survey. Responses were used to assess perceptions of competency and willingness to participate in a BTC program and perceived preparedness of the current community pharmacy practice environment for a BTC class of medications with regard to 8 specific classes of medications.

Results:

The survey response rate was 28%. In all, 78% of respondents agreed or strongly agreed that a BTC class of medications is a change that they would be willing to embrace, and 54% agreed or strongly agreed that their PharmD curriculum provided them with adequate training in laboratory and diagnostic test interpretation. Less than half of the respondents agreed or strongly agreed that community pharmacies are currently equipped with the resources necessary to clinically assess a patient and dispense BTC medications.

Conclusion:

PharmD candidates are prepared and willing to participate in a BTC program but believe that the current community practice environment lacks access to resources necessary to do so.

Keywords

behind-the-counter medications over-the-counter medications pharmacist scope of practice pharmacy education pharmacy students

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Behind the counter availability of certain drugs: public meeting. Web site. https://www.federalregister.gov/articles/2007/11/27/E7-23026/behind-the-counter-availability-of-certain-drugs-public-meeting-comment-period-clarification. Published November 27, 2007. Accessed October 15, 2015.

Ried

Huston

Kucukarslan

. Risks, benefits, and issues in creating a behind-the-counter category of medications. J Am Pharm Assoc. 2011;51(1):26–39.

Government Accountability Office. Nonprescription Drugs: Value of a Pharmacist-Controlled Class has Yet to be Demonstrated. Washington, D.C: Government Accountability Office; 1995.

Government Accounability Office. Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class. Washington, D.C: Government Accountability Office; 2009.

Hunt

Culbertson

Erramouspe

Casperson

. Perceptions of practicing pharmacists in Idaho about a potential behind-the-counter drug program. Ann Pharmacother. 2010;44(9):1403–1409.

Sega

Sullivan

. Assessment of pharmacists’ opinions toward the behind-the-counter category of medications. J Am Pharm Assoc. 2011;51(4):535–538.

Verint. Web site. http://www.verint.com/solutions/customer-engagement-optimization/voice-of-the-customer-analytics/. Accessed October 15, 2015.

U.S. Department of Justice Drug Enforcement Administration. 2006. Combat Methamphetamine Epidemic Act of 2005. Web site. http://www.deadiversion.usdoj.gov/meth/cma2005.htm. Published May, 2006. Accessed October 15, 2015.